secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001493152-22-013852
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Q1 revenue up 6% to $10.4M; net loss narrows to $2.2M from $4.2M
--------------------------------------------------------------------------

- Q1 revenue $10.4M, +6% YoY; net loss improved to $2.2M from $4.2M in Q1 2021.
- Gross margin 48% vs 46% prior year; DSO decreased 27% to 63 days.
- Adjusted EBITDA loss $0.9M, flat YoY; cash $2.9M at March 31, 2022.
- Entered $2M convertible note agreement with BroadOak Fund V, L.P. on May 5, 2022 for working capital.
- Collaboration with Twist Bioscience and Miroculus to automate NGS library prep using digital microfluidics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222013852/0001493152-22-013852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222013852/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-013852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer